*For patients with COPD who seek symptom relief, YUPELRI is the first and only once-daily nebulized LAMA for a full 24 hours of lung function improvement.1
YUPELRI was studied in a two 12-week, randomized, double-blind, placebo-controlled, parallel-group confirmatory studies of once-daily YUPELRI in patients with moderate to very severe COPD. The primary endpoint was change from baseline in trough (predose ) FEV1 at day 85 vs placebo: YUPELRI demonstrated a statistically significant difference vs placebo in both studies. In addition, a prespecified exploratory analysis was performed using serial spirometry on a substudy population over 24 hours on days 84 /85, which showed consistent improvement in FEV1 versus placebo over 24 hours. See results here.
Have you considered the role of nebulization in COPD maintenance therapy?
Nebulizers: a user-friendly option for COPD patients2
YUPELRI delivers consistent control* over 12 weeks.
YUPELRI demonstrated consistent improvements† in trough FEV1 vs placebo over the 12-week study period.1,11*In Study 1, LS mean change from baseline in trough FEV1 on day 85 was 127 mL (YUPELRI, n=189) and -19 mL (placebo, n=191), with a statistically significant difference vs placebo of 146 mL (P<.0001). In Study 2, LS mean change from baseline in trough FEV1 on day 85 was 102 mL (YUPELRI, n=181) and -45 mL (placebo, n=187), with a statistically significant difference of 147 mL (P<.0001).11 †The first measurement was taken at 2 weeks.
Up to 100% of patients with Medicare Part B are covered.† J-CODE J7677 Learn More
†This is not a guarantee of coverage. Site of Care will determine coverage. Check with your patient’s insurance provider for coverage rules and restrictions. In certain limited instances, YUPELRI may be covered through a patient’s Medicare Part D pharmacy benefit.